Biomarkers are the critical missing links in the search for better Parkinson’s disease treatments.
The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate people with Parkinson’s disease and those at greater risk of developing the disease, as well as healthy controls. The goal is to identify one or more biomarkers of Parkinson’s disease progression. This longitudinal study, following over 1,000 participants for up to 8 years, is taking place at 33 clinical sites in the United States, Europe, Israel and Australia.
Critical data and biospecimens are currently available for the research community.
The comprehensive PPMI database and biorepository, includes:
> Clinical and behavioral assessments
> Imaging data
> Biospecimens: cerebral spinal fluid, DNA, RNA, plasma, serum, urine and cell lines
PPMI is made possible by the concerted efforts of a number of collaborators and sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
In late spring, investigators from the Parkinson’s Progression Markers Initiative (PPMI) gathered in New York City for their annual meeting. Also in attendance were a handful of PPMI participants who are members of the PPMI Patient Committee. These research volunteers penned a letter to the PPMI community sharing their gratitude to the many people involved […]
Today The Michael J. Fox Foundation (MJFF) announced a challenge asking data scientists and computational analysts to work with researchers to answer fundamental questions about Parkinson’s that limit our understanding and slow drug testing. The PPMI Data Challenge offers $25,000 each to two teams that develop models to answer either: • What factors at baseline predict […]
The 2016 PPMI annual meeting took place on May 4-5 in New York City. The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners. During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]
On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.
Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson’s Disease indicates that lower concentrations of α-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.